In8bio Inc Stock In The News

INAB Stock  USD 0.31  0.01  3.33%   
Our overall analysis of In8bio's news coverage and content from conventional and social sources shows investors' bearish mood towards In8bio Inc. The specific impact of In8bio news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of In8bio's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using In8bio headlines in addition to utilizing other, more conventional financial analysis modules. Check out In8bio Backtesting and In8bio Hype Analysis.

In8bio Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
https://www.globenewswire.com/news-release/2023/11/20/2783105/0/en/IN8bio-s-INB-200-Demonstrates-Extended-Progression-Free-Survival-in-Patients-with-Newly-Diagnosed-Glioblastoma.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio to Present Data Highlighting Pote...
https://www.globenewswire.com/news-release/2023/11/10/2778199/0/en/IN8bio-to-Present-Data-Highlighting-Potential-of-INB-200-and-INB-400-to-Treat-Patients-with-Newly-Diagnosed-Glioblastoma-Multiforme-at-Society-for-Neuro-Oncology-28th-Annual-Meetin.html
 Neutral
Macroaxis News: globenewswire.com
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
https://www.globenewswire.com/news-release/2023/11/09/2777752/0/en/IN8bio-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio Presents Biologic Correlative Dat...
https://www.globenewswire.com/news-release/2023/11/06/2774075/0/en/IN8bio-Presents-Biologic-Correlative-Data-from-the-INB-200-Phase-1-Trial-in-Newly-Diagnosed-Glioblastoma-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio Presents Positive Data Update fro...
https://www.globenewswire.com/news-release/2023/11/03/2773325/0/en/IN8bio-Presents-Positive-Data-Update-from-Induced-Pluripotent-Stem-Cell-iPSC-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
https://www.globenewswire.com/news-release/2023/11/02/2772464/0/en/IN8bio-to-Present-New-Positive-Data-from-Phase-1-Trial-of-INB-100-at-2023-American-Society-of-Hematology-ASH-Annual-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
https://www.globenewswire.com/news-release/2023/11/01/2771094/0/en/IN8bio-to-Participate-at-the-2023-Truist-Securities-BioPharma-Symposium.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio Completes Dose Escalation in Phas...
https://www.globenewswire.com/news-release/2023/10/12/2759188/0/en/IN8bio-Completes-Dose-Escalation-in-Phase-1-Trial-of-INB-100-a-Potential-First-in-Class-Gamma-Delta-T-Cell-Therapy-for-the-Treatment-of-Leukemias-and-Initiates-Enrollment-for-the-P.html
 Neutral
Macroaxis News: globenewswire.com
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
https://www.globenewswire.com/news-release/2023/09/29/2751940/0/en/IN8bio-Announces-Presentations-at-the-Society-for-Immunology-of-Cancer-SITC-38th-Annual-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
https://www.globenewswire.com/news-release/2023/09/26/2749460/0/en/IN8bio-to-Host-Research-Development-Day-on-its-Gamma-Delta-T-cell-Therapies-on-Thursday-October-12-2023-in-New-York-City.html
 Bullish

In8bio Inc Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide In8bio and other traded companies coverage with news coverage. We help investors stay connected with In8bio headlines for the 26th of November to make an informed investment decision based on correlating the impacts of news items on In8bio Stock performance. Please note that trading solely based on the In8bio Inc hype is not for everyone as timely availability and quick action are needed to avoid losses.
In8bio's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help In8bio Inc investors visualize upcoming and past events in order to time the market based on In8bio Inc noise-free hype analysis.
In8bio stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the In8bio earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about In8bio that are available to investors today. That information is available publicly through In8bio media outlets and privately through word of mouth or via In8bio internal channels. However, regardless of the origin, that massive amount of In8bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of In8bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of In8bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to In8bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive In8bio alpha.

In8bio Largest EPS Surprises

Earnings surprises can significantly impact In8bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-09
2024-03-31-0.18-0.2-0.0211 
2024-08-09
2024-06-30-0.168-0.19-0.02213 
2021-11-10
2021-09-30-0.28-0.250.0310 
2023-03-30
2022-12-31-0.32-0.37-0.0515 
2022-11-10
2022-09-30-0.29-0.34-0.0517 
2022-03-17
2021-12-31-0.26-0.210.0519 
View All Earnings Estimates

In8bio Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to In8bio Inc Stock. Current markets are strongly bearish. About 75% of major world exchanges and indexes are down. See today's market update for more information.
Gurufocus Stories at Macroaxis
25th of November 2024
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral .....
at gurufocus.com 
Investing News at Macroaxis
13th of November 2024
IN8bio stock target cut, analyst sustains buy rating on Q4 loss
at investing.com 
Yahoo News
5th of November 2024
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology Annual M...
at finance.yahoo.com 
Google News at Macroaxis
8th of October 2024
INAB Stock Hits 52-Week Low at 0.23 Amid Market Challenges - Investing.com
at news.google.com 
seekingalpha News
1st of October 2024
IN8bio dips 9, prices 12.4M private placement
at seekingalpha.com 
Google News at Macroaxis
9th of September 2024
IN8bio executives amend employment terms amid strategic changes - Investing.com
at news.google.com 
Yahoo News
4th of September 2024
Acquisition by Goswami Trishna of 250000 shares of In8bio at 0.47 subject to Rule 16b-3
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards In8bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, In8bio's short interest history, or implied volatility extrapolated from In8bio options trading.
When determining whether In8bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of In8bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of In8bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on In8bio Inc Stock:
Check out In8bio Backtesting and In8bio Hype Analysis.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. If investors know In8bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In8bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Return On Assets
(0.78)
Return On Equity
(1.80)
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In8bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.